If you have been reading about GRF(1-29) and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-11-16. Numbers and descriptions here follow the published literature rather than marketing material.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
| Property | Value | Notes |
|---|---|---|
| Molecular weight, DAC form | About 3647 Da | Varies with salt form |
| Molecular weight, non-DAC form | About 3358 Da | MOD GRF(1-29) |
| Solubility class | Water soluble | Also dissolves in polar solvents |
| Reported half-life, DAC form | About five to eight days | Values from human studies |
| Common synonyms | CJC-1295; MOD GRF(1-29) | Name depends on variant |
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
Pudafensine (INNTooltip International Nonproprietary Name; developmental code name IP2015 among others) is a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) which is under development for the treatment of erectile dysfunction, neuropathic pain, trigeminal neuralgia, vulvodynia, female sexual dysfunction, pain, and substance-related disorders. It is taken orally. The drug has been found to induce penile erection in male rodents and to increase genital blood flow and paracopulatory behaviors in female rodents. A close analogue of pudafensine is the earlier SNDRI NS18283. Pudafensine is under development by Initiator Pharma. As of July 2025, it is in phase 2 clinical trials for erectile dysfunction, phase 1 trials for neuropathic pain, trigeminal neuralgia, and vulvodynia, and the preclinical research stage of development for female sexual dysfunction, pain, and substance-related disorders.
electron transport in the mitochondrial ETC, by shuttling electrons from mitochondrial complexes like nicotinamide adenine dinucleotide (NADH), ubiquinone reductase (complex I), and succinate ubiquinone reductase (complex II), the fatty acids and branched-chain amino acids oxidation (through flavin-linked dehydrogenases) to ubiquinol–cytochrome-c reductase (complex III) of the ETC: CoQ10 participates in fatty acid and glucose metabolism by transferring electrons generated from the reduction of fatty acids and glucose to electron acceptors; antioxidant activity as a lipid-soluble antioxidant together with vitamin E, scavenging reactive oxygen species and protecting cells against oxidative stress, inhibiting the oxidation of proteins, DNA, and use of vitamin E.
The Gross domestic product (GDP) of the state was 62.7 billion euros in 2018, accounting for 1.9% of German economic output. GDP per capita adjusted for purchasing power was 30,400 euros or 101% of the EU27 average in the same year. The GDP per employee was 95% of the EU average. The GDP per capita was the lowest of all states in West Germany. In 2017, Schleswig-Holstein had an export surplus for the first time since 1989: export 22.6 billion euros/ import 20.8 billion euros.
==== August 2015 norovirus ==== A norovirus outbreak occurred in August 2015 at a Simi Valley, California, location, ultimately affecting more than 200 people. Ventura County health inspectors found health violations during inspections following the outbreak. In January 2016, a federal grand jury issued a subpoena as part of a criminal investigation into the outbreak.
Sources: en.wikipedia.org
== Further reading == Markwell, John; Brooks, David W. (2002). "Broken Links: The Ephemeral Nature of Educational WWW Hyperlinks". Journal of Science Education and Technology. 11 (2): 105–108. Bibcode:2002JSEdT..11..105M. doi:10.1023/A:1014627511641. Gomes, Daniel; Silva, Mário J. (2006). "Modelling Information Persistence on the Web" (PDF). Proceedings of the 6th International Conference on Web Engineering. ICWE'06. Archived from the original (PDF) on 2011-07-16. Retrieved 14 September 2010. Dellavalle, Robert P.; Hester, Eric J.; Heilig, Lauren F.; Drake, Amanda L.; Kuntzman, Jeff W.; Graber, Marla; Schilling, Lisa M. (31 October 2003). "Going, Going, Gone: Lost Internet References". Science. 302 (5646): 787–788. doi:10.1126/science.1088234. PMID 14593153. Koehler, Wallace (1999). "An Analysis of Web Page and Web Site Constancy and Permanence". Journal of the American Society for Information Science. 50 (2): 162–180. doi:10.1002/(SICI)1097-4571(1999)50:2<162::AID-ASI7>3.0.CO;2-B. Sellitto, Carmine (2005). "The impact of impermanent Web-located citations: A study of 123 scholarly conference publications" (PDF). Journal of the American Society for Information Science and Technology. 56 (7): 695–703. doi:10.1002/asi.20159.
Endocrine signals are called hormones. Hormones are produced by endocrine cells and they travel through the blood to reach all parts of the body. Specificity of signaling can be controlled if only some cells can respond to a particular hormone. Endocrine signaling involves the release of hormones by internal glands of an organism directly into the circulatory system, regulating distant target organs. In vertebrates, the hypothalamus is the neural control center for all endocrine systems. In humans, the major endocrine glands are the thyroid gland and the adrenal glands. The study of the endocrine system and its disorders is known as endocrinology.
== History == BCSIR traces its roots back to the days of East Pakistan. East Regional Laboratories of Pakistan Council of Scientific and Industrial Research (PCSIR) was established in Dhaka in 1955. Subsequently, PCSIR laboratories were established in Rajshahi (1965) and in Chittagong (1967). After the independence of Bangladesh in 1971, BCSIR was established by a resolution of the Government of the People's Republic of Bangladesh which subsequently was reconstituted as the Bangladesh Council of Scientific and Industrial Research through a Presidential Ordinance namely Ordinance No. (V) of 1978.
==== First scientific synthetic dye: picric acid ==== The first synthetic dye was picric acid. It was prepared in a laboratory in 1771, and commercially produced by M. Guinon in Lyon in 1845. It dyed silk fabric yellow; however the color fastness properties were not good, thus it had very limited commercial success. It was, however, purchased in limited amounts by French dyers.
Grammostola mechanotoxin #4 (GsMTx-4, GsMTx4, GsMTx-IV), also known as M-theraphotoxin-Gr1a (M-TRTX-Gr1a), is a neurotoxin isolated from the venom of the spider Chilean rose tarantula Grammostola spatulate (or Grammostola rosea). This amphiphilic peptide, which consists of 35 amino acids, belongs to the inhibitory cysteine knot (ICK) peptide family. It reduces mechanical sensation by inhibiting mechanosensitive channels (MSCs). GsMTx-4 also serves as a cationic antimicrobial peptide against Gram-positive bacteria.
Sources: en.wikipedia.org
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.
The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.